Sartorius Stedim Biotech S.A. (FRA:56S1)

Market Cap	17.78B -14.1%
Revenue (ttm)	2.97B +6.7%
Net Income	265.60M +51.7%
EPS	2.73 +50.9%
Shares Out	n/a
PE Ratio	66.95
Forward PE	35.72
Dividend	0.69 (0.40%)
Ex-Dividend Date	Mar 31, 2026

Volume	n/a
Average Volume	14
Open	177.60
Previous Close	180.80
Day's Range	177.60 - 177.60
52-Week Range	154.60 - 223.40
Beta	n/a
RSI	41.50
Earnings Date	Feb 3, 2026

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog...

• Industry: Laboratory Analytical Instruments
• Founded: 1978
• Employees: 10,265
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 56S1

Financial Performance

In 2025, Sartorius Stedim Biotech's revenue was 2.97 billion, an increase of 6.74% compared to the previous year's 2.78 billion. Earnings were 265.60 million, an increase of 51.68%.